China Health Report
SEE OTHER BRANDS

Fresh news on health and wellness in China

China Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on China Health Report.

Press releases published on August 8, 2025

Scalp Health Market is Expected to Reach a Valuation of USD 18.4 Billion in 2035, Says Fact.MR

Scalp Health Market is Expected to Reach a Valuation of USD 18.4 Billion in 2035, Says Fact.MR

From Dandruff to Diagnostics: Scalp Health Emerges as Wellness-Critical Segment with USD 18.4 Billion Potential. ROCKVILLE, MD, UNITED STATES, August 8, 2025 /⁨EINPresswire.com⁩/ -- According to Fact.MR, a market research and competitive intelligence …

Global Orthopedic Power Smart: Schnecon Technology Innovations at ORS-CHINA 2025

Global Orthopedic Power Smart: Schnecon Technology Innovations at ORS-CHINA 2025

SHANGHAI, SHANGHAI, CHINA, August 8, 2025 /⁨EINPresswire.com⁩/ -- The global orthopedic medical device market is on an accelerated trajectory of growth, driven by an aging population, an increasing prevalence of joint and spine-related disorders, and a …

Top Orthopedic Device Suppliers Appeared At The 2nd National Conference Of Orthopedic And Spine Surgery Suppliers

Top Orthopedic Device Suppliers Appeared At The 2nd National Conference Of Orthopedic And Spine Surgery Suppliers

SHANGHAI, SHANGHAI, CHINA, August 8, 2025 /⁨EINPresswire.com⁩/ -- The medical device industry, particularly within the specialized field of orthopedics, is a cornerstone of modern healthcare. Innovations in this sector are constantly pushing the boundaries …

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions